EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
The claims are expected to provide protection into 2041, unless extended further.
- The claims are expected to provide protection into 2041, unless extended further.
- “Importantly, this patent for the dose strength in RMS patients covers all salt and free acid forms of vidofludimus calcium.
- In the United States, these patents provide protection into 2041, unless extended further.
- On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.